OMNICELL, INC.OMCLEarnings & Financial Report
Omnicell, Inc. is an American multinational healthcare technology company headquartered in Mountain View, CA. It manufactures automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. Its products are sold under the brand names Omnicell and EnlivenHealth.
OMCL Q1 FY2026 Key Financial Metrics
Revenue
$309.9M
Gross Profit
$140.4M
Operating Profit
$186.4M
Net Profit
$11.4M
Gross Margin
45.3%
Operating Margin
60.1%
Net Margin
3.7%
YoY Growth
14.9%
EPS
$0.25
OMNICELL, INC. Q1 FY2026 Financial Summary
OMNICELL, INC. reported revenue of $309.9M (up 14.9% YoY) for Q1 FY2026, with a net profit of $11.4M (3.7% margin). Cost of goods sold was $169.5M.
Key Financial Metrics
| Total Revenue | $309.9M |
|---|---|
| Net Profit | $11.4M |
| Gross Margin | 45.3% |
| Operating Margin | 60.1% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
OMNICELL, INC. Q1 FY2026 revenue of $309.9M breaks down across 2 segments, led by Product revenues at $174.8M (56.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product revenues | $174.8M | 56.4% |
| Service revenues | $135.1M | 43.6% |
OMNICELL, INC. Annual Revenue by Year
OMNICELL, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2B).
OMNICELL, INC. Quarterly Revenue & Net Profit History
OMNICELL, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $309.9M | +14.9% | $11.4M | 3.7% |
| Q4 FY2025 | $314.0M | +2.3% | N/A | N/A |
| Q3 FY2025 | $310.6M | +10.0% | $5.5M | 1.8% |
| Q2 FY2025 | $290.6M | +5.0% | $5.6M | 1.9% |
| Q1 FY2025 | $269.7M | +9.6% | $-7.0M | -2.6% |
| Q4 FY2024 | $306.9M | +18.6% | N/A | N/A |
| Q3 FY2024 | $282.4M | -5.4% | $8.6M | 3.1% |
| Q2 FY2024 | $276.8M | -7.4% | $3.7M | 1.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $276.8M | $282.4M | $306.9M | $269.7M | $290.6M | $310.6M | $314.0M | $309.9M |
| YoY Growth | -7.4% | -5.4% | 18.6% | 9.6% | 5.0% | 10.0% | 2.3% | 14.9% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.29B | $2.30B | $2.12B | $2.15B | $2.15B | $1.95B | $1.97B | $2.00B |
| Liabilities | $1.09B | $1.07B | $877.6M | $894.4M | $881.9M | $727.7M | $742.9M | $747.5M |
| Equity | $1.20B | $1.23B | $1.24B | $1.26B | $1.26B | $1.22B | $1.23B | $1.26B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $58.7M | $22.8M | $56.3M | $25.9M | $42.8M | $28.3M | $30.4M | $54.5M |